Research Library

Tirzepatide: A Research Overview

Tirzepatide is one of the best-developed examples of a modern incretin-receptor research program. The molecule began as LY3298176 and is now the active pharmaceutical ingredient in two Eli Lilly fi...

Tirzepatide Full Evidence Review

A source-bounded review of Tirzepatide identity, dual-receptor pharmacology, clinical evidence, safety, regulatory context, non-Lilly material boundaries, and unresolved evidence gaps.

GHK-Cu Full Evidence Review

GHK-Cu is best understood as an equilibrating Cu(II)-coordination system involving the tripeptide glycyl-L-histidyl-L-lysine. Its coordination chemistry is substantially better established than its...

Retatrutide Identity and Quality: Connecting the Material to the Evidence

Retatrutide’s clinical research is tied to a precisely defined molecule. Connecting any tested material to that evidence requires more than matching the name—it requires credible identity, content,...

MRI-Measured Liver Fat in the LY3437943 Phase 2 Substudy

Investigators reported striking liver-fat changes in a randomized LY3437943 substudy—one of the most closely watched findings outside the primary body-weight and glycemic endpoints. The study offer...

Understanding Retatrutide, Tirzepatide, and Semaglutide Trial Comparisons

Retatrutide, tirzepatide, and semaglutide represent three stages in the development of incretin-based metabolic research: single-, dual-, and triple-receptor strategies. Comparing them is scientifi...

Retatrutide Safety: What the Evidence Currently Shows

Retatrutide’s clinical program has already produced a recognizable tolerability profile. Understanding what researchers observed—and what longer follow-up still needs to establish—is essential to e...

Retatrutide Phase 3: What the TRIUMPH Program Has Actually Shown

TRIUMPH is an unusually broad Phase 3 program spanning general obesity, type 2 diabetes, cardiovascular disease, osteoarthritis, sleep apnea, head-to-head comparison, treatment escalation, longer-t...

What Is Retatrutide? Why the Triple-Agonist Design Matters

Lilly’s LY3437943 represents one of the most ambitious ideas in modern metabolic-peptide research: combining GIP, GLP-1, and glucagon-receptor activity within one investigated molecule. The program...

What the LY3437943 DXA Substudy Reported About Body Composition

The LY3437943 body-composition substudy drew interest because large body-weight changes were accompanied by substantial changes in measured fat mass. The next research question is how lean tissue, ...